|
 |
 |
 |
 |
||||
 |
|
|
|
|
|
|
||||||||||||||||||||
|
|||||||||||||||||||||||||
News 26 April 2010 Immunosolv products will be distributed in Canada and the USA by Cedarlane Laboratories and in Japan by Funakoshi. 1 December 2009 Enabling technologies that emulate in vitro the physiological processes that are required for the proper regulation of cell populations in vivo are essential for the effective production and delivery of therapeutic cells. ImmunoSolv's Dead-Cert technology provides an in vitro dead-cell removal system that very effectively replaces the phagocytes that carry out this activity which is so essential for the normal regulation of all tissues in vivo. Dead-Cert technology significantly improves the quality, through removal of non-viable cells, of cell populations for a multitude of research applications. Because of its capacity to remove inhibitory dead cells and debris, the technology is set to markedly improve bioprocessing of cells for clinical use, improve the quality of stored cells and extend product shelf life. The objectives of the present project are (1) to produce a clinical-grade product that can be applied to therapeutic cell populations to improve their viability and consequent efficacy, (2) to prove that the clinical grade product is efficacious on model cell populations, and (3) to assess the regulatory hurdles and route into the clinic in the EU and US. To achieve these aims, ImmunoSolv will work with two major partners: (i) Angel Biotechnology, the only UK company licensed to produce GMP-certified cells and (ii) The Weinberg Group, which has extensive expertise in addressing the regulatory issues for successful product entry into the clinical EU and US markets. A successful outcome will accelerate ImmunoSolv's product entry into the therapeutic cells space, build value in the company and promote the UK's leadership in introducing novel enabling technologies into the regenerative medicine field. It is anticipated that successful development of a clinical Dead-Cert product and regulatory route will result in inclusion of this valuable technology in clinical trials within two years. 24 November 2009 Dead-Cert® Nanoparticles beat off stiff competition to win this prestigious award, judged by a panel of industry experts, which acknowledges the most innovative product from an East of Scotland life science institution or company. 23 September 2009 June 2009 May 2009 August 2008 Cancer and arthritis drugs could become much cheaper to make by using magnets during the manufacturing process, researchers say. A University of Edinburgh team has developed a more streamlined method of making protein-based drugs, which are made by growing cell cultures in a lab. Magnets coated with special antibodies were used to draw out dead cells. The scientists said the remaining cells were then 100% more efficient in making the proteins used to create drugs. Prof Chris Gregory, of the university's Centre for Inflammation Research, said the technique could cut the price of NHS medicines like breast cancer treatment Herceptin and arthritis drug Enbrel.
He said the findings could also have implications for vaccine development and stem cell research.
"We are essentially mimicking what happens in the body when scavenger cells remove dead and abnormal cells," he said.
"If the dead cells are not removed, then this affects how healthy cells behave.
"Not only will this make the production of drugs more efficient, but it will also streamline research into new medicines which use cell culture."
April 2008 Following the successful technological developments facilitated by SMART, ImmunoSolv has secured seed-round funding from two angel groups, Firth Ventures and Grampian Bio-Partners, together with funding from the Scottish Government (Scottish Seed Fund). The funding will be used primarily to take ImmunoSolv’s novel antibody-based dead-cell detection and removal technology to market. Jan 2007 ImmunoSolv won a prestigious SMART award from the Scottish Executive. These highly competitive awards are designed to help new and existing businesses improve their competitiveness by developing leading-edge products or processes that have real commercial value. |
